Recombinomics | Elegant Evolution

Home Founder What's New In The News Consulting

H1N1 Consulting

Paradigm Shift

Viral Evolution

Intervention Monitoring

Vaccine Screening

Vaccine Development

Expression Profiling

Drug Discovery

Custom Therapies


Audio:May20 Jun17 Jul15 Aug19 RSS Feed twitter News Now                         
Live feed of underlying pandemic map data here

H1N1 Tamiflu and Relenza Resistance in Kansas Case NOT
Recombinomics Commentary 23:40
August 25, 2010

On August 26 the CDC notified Recombinomics that the GISAID entry on antiviral resistance is in ERROR.  A/Kansas/05/2010 is SENSITIVE to oseltamivir and Zanamivir.

The US CDC released an NA sequence, A/Kansas/05/2010, today (at GISAID), which had in vivo Tamiflu (oseltamivir) and Relenza (zanamivir) resistance.  The sample was collected March 17, 2010 and had two non-synonymous changes, S363N and I 466M (S364N and I467M in N1 numbering). 

A second sequence, A/Connecticut/23/2009, was also released by the CDC today, and it also had I466M, which was also on an earlier sequence from Poland, A/Poland/37/2009.  None of the above sequences had H274Y.

Resistance to the two first line neuramindase inhibitors (and it is likely that the M2 sequence also has S31N, conferring resistance to adamantines) in the same sequence is cause for concern.

Information on the resistance in the patients from Connecticut and Poland would be useful.
Media Links

Recombinomics Presentations

Recombinomics Publications

Recombinomics Paper at Nature Precedings

Home | Founder | What's New | In The News | Contact Us

© 2010 Recombinomics.  All rights reserved.